NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Thursday, October, 31st. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.14 by $0.10. The company had revenue of $605.30 million for the quarter, compared to analyst estimates of $597.09 million. IDEXX Laboratories had a return on equity of 405.71% and a net margin of 17.99%. The firm's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.05 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Friday, January 31st 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories will be holding an earnings conference call on Friday, January 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

IDEXX Laboratories updated its FY20 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $5.30-5.46 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.56. The company issued revenue guidance of $2.61-2.65 billion, compared to the consensus revenue estimate of $2.63 billion.

6 brokerages have issued 12 month price targets for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they anticipate IDEXX Laboratories' stock price to reach $293.33 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Media stories about IDXX stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IDEXX Laboratories earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 1,310,000 shares, a decline of 10.3% from the November 28th total of 1,460,000 shares. Based on an average daily trading volume, of 463,700 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.6% of the shares of the company are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Netflix (NFLX), Adobe (ADBE), Alibaba Group (BABA), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Walt Disney (DIS).

IDEXX Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Welch & Forbes LLC (0.21%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%), Howland Capital Management LLC (0.15%), Davis R M Inc. (0.14%), Chicago Capital LLC (0.11%) and Bourne Lent Asset Management Inc. (0.11%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DNB Asset Management AS, First Hawaiian Bank, Davis R M Inc., Cribstone Capital Management LLC, State of Alaska Department of Revenue and Calamos Wealth Management LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Mckinley Capital Management LLC Delaware, Johanson Financial Advisors Inc., Aurora Investment Managers LLC., Pensionfund DSM Netherlands, Chapman Investment Management LLC, Ambassador Advisors LLC and Pensionfund Sabic. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $280.07.

IDEXX Laboratories has a market capitalization of $24.02 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]